NEW YORK (TheStreet) -- Celgene (CELG - Get Report) is a "very, very cheap" stock, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment Thursday
The biotechnology stock, an AAP holding, missed revenue estimates but beat earnings expectations. Celgene also saw sales of Revlimid, its number one-selling drug, come in lower than expected. Cramer noted the company also reaffirmed its previous guidance but did not raise it.
Currently, the stock trades at 18 times earnings, in line with several large-cap pharmaceutical companies despite its growth rate. Cramer suggested that investors are not willing to pay up for companies that are "spending for earnings."
He pointed out a similar circumstance with Under Armour (UA) where the company is growing incredibly fast but the stock is lower following its top- and bottom-line earnings results.
- - Written by Bret Kenwell in Petoskey, Mich.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts